

Using Biologics to Improve Multi Oral Immunotherapy (mOIT) Outcomes (COMBINE Study)

Seeking participants with peanut and multiple food allergies for a clinical trial involving mOIT and biologic drugs.



Principal Investigator: Dr. Stephanie Leonard
Director, Food Allergy Center at Rady Children's Hospital San Diego

Description: Our center is seeking people aged 5-21 years old to participate in this clinical trial. We will include participants with proven allergies to 2 or 3 different foods, one of which must be peanut. Our goal is to determine if using biologics (omalizumab and dupilumab) multi oral immunotherapy (mOIT) will increase tolerance to multiple food allergens.

The biologics to be used in the clinical trial are Omalizumab and Dupilumab. These biologics are FDA approved for other conditions, and are being used experimentally in people with food allergies in this clinical trial. Omalizumab (Xolair) is an injectable prescription medication that treats moderate to severe persistent allergic asthma in patients 6 years of age or older. Dupilumab (Dupixent) is an injectable non-steroid prescription medication that treats moderate to severe eczema.

If interested in learning more about the COMBINE study, please email Amy Grissinger, NP
agrissinger@rchsd.org